| Intellia Thera CS (NTLA) | |||
|---|---|---|---|
| 23.6 0.33 (1.42%) | 05-03 16:00 | ||
| Open: | 24.44 | Pre. Close: | 23.27 |
| High: | 24.99 | Low: | 23.42 |
| Volume: | 1,276,480 | Market Cap: | 2,276(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: |  |
| Target: | Six months: 32.08  One year: 37.47 |
| Support: | Support1: 22.46 Support2: 19.37 |
| Resistance: | Resistance1: 27.46 Resistance2: 32.08 |
| Pivot: | 21.81  |
| Moving Averages: | MA(5): 22.55 MA(20): 22.64 MA(100): 27.04 MA(250): 32.58 |
| MACD: | MACD(12,26): -0.96 Signal(12,26,9): -1.33 |
| %K %D: | %K(14,3): 65.18 %D(3): 52.28 |
| RSI: | RSI(14): 50.91 |
| 52-Week: | High: 47.48 Low: 19.37 Change(%): -46.2 |
| Average Vol(K): | 3-Month: 1485 10-Days: 1174 |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | 25.02 - 25.116 | 25.116 - 25.212 |
| Low: | 23.176 - 23.288 | 23.288 - 23.399 |
| Close: | 23.422 - 23.591 | 23.591 - 23.76 |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ NTLA ] has closed below upper band by 0.9%. Bollinger Bands are 35.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
| Company profile |
|---|
| Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. |
| Stock chart |
|---|
 |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Underperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: NASDAQ Global Market | |
| Sector: Healthcare | |
| Industry: Biotechnology | |
| Shares Out. (M) | |
| Shares Float (M) | 96.11 |
| % Held by Insiders | 94530000.00 |
| % Held by Institutions | 1.33 |
| Shares Short (K) | 12620 |
| Shares Short Prior Month (K) | |
| Stock Financials | |
|---|---|
| EPS | -506320000.000 |
| Book Value (p.s.) | |
| Profit Margin | |
| Operating Margin | 7.00 |
| Return on Assets (ttm) | 297.4 |
| Return on Equity (ttm) | -22.8 |
| Qtrly Rev. Growth | 36270000.0 |
| Gross Profit (p.s.) | |
| Sales Per Share | -23.389 |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | -5.42 |
| Operating Cash Flow (M) | |
| Levered Free Cash Flow (M) | -394.09 |
| Stock Valuation | |
|---|---|
| PE Ratio | |
| PEG Ratio | -0.13 |
| Price to Book value | |
| Price to Sales | -1.01 |
| Price to Cash Flow | 3.76 |
| Stock Dividends | |
|---|---|
| Dividend | |
| Dividend Yield | |
| Dividend Growth | 14830000.000 |
